IPO round-up: CardioDx back on; Lombard gets US listing
This article was originally published in Clinica
Diagnostic specialist CardioDx has resurrected its IPO plans, but did not give details of how much it hopes to raise. The company already tried to go public last November, targeting five million shares at $14-16 each, but postponed it due to poor market conditions. Before this, it had said it hoped to bring in $86m. It first filed for an IPO in July 2013.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.